Company Overview
| Stock Name | Basecare-B |
|---|---|
| Stock Code | 02170 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 中國輔助生殖基因檢測解決方案的創新平台,提供PGT-A試劑盒等植入前基因檢測產品,並開發PGT-M、PGT-SR、CNV、WES試劑盒及基因檢測設備儀器,為醫院和生殖診所提供一站式定制化綜合解決方案。 |
| Listing Date | 2021-02-08 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國江蘇省蘇州市蘇州工業園區星湖街218號生物納米園A3樓101室 |
| Business Address (Hong Kong) | 香港灣仔皇后大道東248號陽光中心40樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | basecare.cn |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 27.36 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 500 shares |
| Entry Threshold | HK$ 13,680 |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2021-01-27 to 2021-02-01 |
| Global Offering Shares | 66,667,000 shares |
| HK Public Offer Shares (Initial) | 6,667,000 shares (10.0%) |
| Public Offer Lots (Initial) | 13,334lots (Pool A6,667lots,Pool B6,667lots) |
| International Placing Shares (Initial) | 60,000,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 266,667,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 38.3% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 1,824,009,120 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 500 | HK$ 13,680 |
| 2 lots | 1,000 | HK$ 27,360 |
| 3 lots | 1,500 | HK$ 41,040 |
| 4 lots | 2,000 | HK$ 54,720 |
| 5 lots | 2,500 | HK$ 68,400 |
| 6 lots | 3,000 | HK$ 82,080 |
| 7 lots | 3,500 | HK$ 95,760 |
| 8 lots | 4,000 | HK$ 109,440 |
| 9 lots | 4,500 | HK$ 123,120 |
| 10 lots | 5,000 | HK$ 136,800 |
| 12 lots | 6,000 | HK$ 164,160 |
| 14 lots | 7,000 | HK$ 191,520 |
| 16 lots | 8,000 | HK$ 218,880 |
| 18 lots | 9,000 | HK$ 246,240 |
| 20 lots | 10,000 | HK$ 273,600 |
| 30 lots | 15,000 | HK$ 410,400 |
| 40 lots | 20,000 | HK$ 547,200 |
| 50 lots | 25,000 | HK$ 684,000 |
| 60 lots | 30,000 | HK$ 820,800 |
| 70 lots | 35,000 | HK$ 957,600 |
| 80 lots | 40,000 | HK$ 1,094,400 |
| 90 lots | 45,000 | HK$ 1,231,200 |
| 100 lots | 50,000 | HK$ 1,368,000 |
| 120 lots | 60,000 | HK$ 1,641,600 |
| 140 lots | 70,000 | HK$ 1,915,200 |
| 160 lots | 80,000 | HK$ 2,188,800 |
| 180 lots | 90,000 | HK$ 2,462,400 |
| 200 lots | 100,000 | HK$ 2,736,000 |
| 300 lots | 150,000 | HK$ 4,104,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 400 lots | 200,000 | HK$ 5,472,000 |
| 500 lots | 250,000 | HK$ 6,840,000 |
| 600 lots | 300,000 | HK$ 8,208,000 |
| 700 lots | 350,000 | HK$ 9,576,000 |
| 800 lots | 400,000 | HK$ 10,944,000 |
| 900 lots | 450,000 | HK$ 12,312,000 |
| 1,000 lots | 500,000 | HK$ 13,680,000 |
| 1,200 lots | 600,000 | HK$ 16,416,000 |
| 1,400 lots | 700,000 | HK$ 19,152,000 |
| 1,600 lots | 800,000 | HK$ 21,888,000 |
| 1,800 lots | 900,000 | HK$ 24,624,000 |
| 2,000 lots | 1,000,000 | HK$ 27,360,000 |
| 3,000 lots | 1,500,000 | HK$ 41,040,000 |
| 4,000 lots | 2,000,000 | HK$ 54,720,000 |
| 5,000 lots | 2,500,000 | HK$ 68,400,000 |
| 6,667 lots | 3,333,500 | HK$ 91,204,560 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| HK Market Cap | HK$ 129.4M |
| Est. Threshold | HK$ 9.39B |
| Analysis Result | HK market cap below threshold, need +7157% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 7,296,009,120 |
|---|---|
| H-Share Market Cap (at Offer Price) | HK$ 2,026,676,076 |
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不适用(公司处于亏损状态) |
| Profit/Loss Status | 亏损人民币534.0百万元 |
| Period-End Cash Balance | 人民币24.2百万元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2018 | 2019 |
|---|---|---|
| Revenue | 32,609 | 55,685 |
| Cost of sales | -24,472 | -29,432 |
| Gross profit | 8,137 | 26,253 |
| Other income and gains, net | 3,999 | 3,958 |
| Selling and distribution expenses | -10,866 | -11,011 |
| Administrative expenses | -34,243 | -77,990 |
| Operating profit | -51,816 | -88,730 |
| Net finance costs | -927 | -11,316 |
| Share of associates and JVs | -174 | -776 |
| Profit before tax | -157,005 | -5,530,570 |
| Income tax expense | -5,069 | -22,290 |
| Profit for the year | -157,700 | -53,533,997 |
| Profit attributable to owners | -154,877 | -5,311,336 |
Income Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 27.7 |
|---|---|
| First Day Open | HK$ 30.0 |
| First Day Change | 1.24% |
| First Day Volume | 50895400.0 |
| First Day Turnover | 1543960000.0 |
| Use of Proceeds | 1、約30%或515.0百萬港元將分配予我們的核心產品PGT-A試劑盒;
2、約20%或343.3百萬港元將用于PGT-M試劑盒的臨床試驗、注冊申報及商業化;
3、約30%或515.0百萬港元將分配用于我們其他產品的開發、臨床試驗及注冊申報;
4、約10%或171.7百萬港元將用于提高我們的研發能力及提升我們的技術;
5、約10%或171.7百萬港元將用作我們的營運資本及一般企業用途。 |
Underwriting Syndicate
Sole Sponsor (1)
中信证券(香港)有限公司 CE AAK249
Overall Coordinators (3)
Joint Bookrunners (7)
Joint Lead Managers (8)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Affin Hwang Asset Management Berhad | 77,524,560 HKD | — | 4.30% | — | 6 months | 2021-08-08 |
| 2 | CRF Investment Holdings Company Limited | 155,062,800 HKD | — | 8.50% | — | 6 months | 2021-08-08 |
| 3 | Foresight Orient Global Superior Choice SPC | 38,755,440 HKD | — | 2.10% | — | 6 months | 2021-08-08 |
| 4 | Lake Bleu Prime Healthcare Master Fund Limited | 155,062,800 HKD | — | 8.50% | — | 6 months | 2021-08-08 |
| 5 | OrbiMed Funds | 155,062,800 HKD | — | 8.50% | — | 6 months | 2021-08-08 |
| 6 | WinTwin Capital Limited | 77,524,560 HKD | — | 4.30% | — | 6 months | 2021-08-08 |
| 7 | 常春藤资产管理(香港)有限公司 | 38,755,440 HKD | — | 2.10% | — | 6 months | 2021-08-08 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 梁波 | — |
| Company Secretary | 戴靜、嚴洛鈞 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 梁波直接及透過貝康投資合共持有約34.25%權益;貝康投資持有13.53%;高瓴香港持有H股5.11%(或內資股及未上市外資股3.96%);中誠方圓二期持有5.70%;元禾原點持有4.61%。 |
|---|




